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We examine bias in Markov models of diseases, including both chronic and infec-
tious diseases. We consider two common types of Markov disease models: ones where
disease progression changes by severity of disease, and ones where progression of dis-
ease changes in time or by age. We find sufficient conditions for bias to exist in models
with aggregated transition probabilities when compared to models with state/time de-
pendent transition probabilities. We also find that when aggregating data to compute
transition probabilities, bias increases with the degree of data aggregation. We illus-
trate by examining bias in Markov models of Hepatitis C, Alzheimer’s disease, and
lung cancer using medical data and find that the bias is significant depending on the
method used to aggregate the data. A key implication is that by not incorporating
state/time dependent transition probabilities, studies that use Markov models of dis-
eases may be significantly overestimating or underestimating disease progression. This
could potentially result in incorrect recommendations from cost-effectiveness studies
and incorrect disease burden forecasts.
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1 Introduction
Markov models are commonly used to simulate diseases when evaluating various medical
interventions. Modeling diseases allows for the consideration of long term consequences and
other implications not practical via clinical trials. Examples include an analysis of cost-
effectiveness of expanded HIV screening in the US (1; 2), an analysis of the optimal age
of vaccination (3), the optimal timing of liver transplantation (4; 5), and an analysis of
dynamic multi-drug therapies for HIV (6). Markov models are also used to forecast and
estimate future morbidity, mortality, prevalence, and costs of various diseases (7). Markov
models of diseases are often coupled with clinical trial data to determine the cost-effectiveness
of medical interventions. Given the limited amount of resources available, Markov models
of diseases can potentially be a relatively inexpensive, yet powerful tool to evaluate medical
interventions.
However, due to limited disease data or model complexity, simplifying assumptions are
made in many Markov disease models. In this paper, we analyze the effect of a common
simplification, namely, that of modeling diseases that have nonlinear progression with Markov
models that assume constant progression. The assumption of constant disease progression is
used in many disease studies (8; 9; 10; 11; 12; 13; 14; 15; 16). Studies often assume constant
disease progression when there is insufficient patient data to characterize non-linearities
or changes over time. Constant progression is also often assumed in order to reduce the
model’s complexity, particularly when deriving analytical results. In Kirkizlar, et al, (17),
for example, the authors used a reduced the state space model of Hepatitis C (HCV) for
analytical tractability. Consequently, the model did not allow for disease progression to
change as a function of disease severity. The reduced state space was necessary to construct
a dynamic policy of testing for the disease.
This study explores bias in Markov models of disease when constant disease progression
is assumed between states, where bias is the over- or underestimation of overall disease
progression. We consider diseases where progression (i.e., transition probabilities) depends
on the severity of the disease (i.e., state) and diseases where progression varies with time
(i.e., age, time spent in a state). In both cases, we use Markov models and compare the
use of state/time dependent transition probabilities with the use of transition probabilities
that assume constant progression. We make such a comparison in order to determine if,
and under what conditions, Markov models that assume linear progression underestimate or
overestimate disease progression. We then use medical data to assess the magnitude of the
2
ACCEPTED MANUSCRIPT 
bias for HCV, Alzheimer’s disease, and lung cancer.
Previous work on this topic is limited. Scherrer (18), motivated by the same problem,
considered bias in the first two periods of the Markov chain in a Markov model of lung cancer
and found conditions for bias to exist. Scherrer compared a model with time dependent tran-
sition probabilities to one where the probability of acquiring lung cancer did not depend on
the number of years an individual has smoked. A study by Bruinvels and colleagues (19) is
related in that it demonstrated the effect that using yearly probabilities instead of rates has
on a Markov cohort simulation. Their study contained numerical analysis which illustrated
the magnitude of the bias. Davis, et al. (20) examines the problem of estimating transi-
tion probabilities from aggregate data generated, and Yi, et al. (21) estimates transition
probabilities for the specific case of HCV.
In non-health related literature, there has been a great deal of study on Markov chains
in general. State space reduction techniques and the lumpability of Markov chains are par-
ticularly noteworthy. State space reduction techniques can be employed on a Markov chain
that has prohibitively many states or dimensions to reduce it to one with fewer in order to
make computations feasible and arrive at a steady state distribution (22; 23). Under special
conditions, the states of a Markov chain may partitioned into “lumps” to form aggregated
states that also satisfy the Markov property. Aggregation/disaggregation techniques have
also been developed to estimate stationary distributions for large Markov chains. Marek,
et. al. (24), for example, developed an iterative algorithm where the steady state distribu-
tion of a large Markov chain is estimated by computing the steady state distribution of an
aggregated Markov chain. The algorithm finishes if, and when, the probability distribution
of the disaggregated Markov chain converges to a vector under a given norm. Fortunately,
Markov chains of diseases often have relatively small state spaces. The diseases considered
in this study have the additional benefit that they are modeled with Markov chains that
have special structure. We are able to exploit this fact to arrive at closed form expressions
rather than using iterative algorithms or approximations.
Also noteworthy in regards to our study are papers that use the Kullback-Leibler (K-L)
divergence rate in comparing two Markov chains (25; 26). The K-L divergence rate can
be used to compare two Markov chains over the same state space. As the divergence rate
increases, the Markov chains are considered more “different.” It is well known that the K-L
divergence rate, however, is not a distance metric since it is not symmetric, nor does it satisfy
the triangle inequality. More importantly, at present the K-L divergence rate for comparing
Markov chains with different state spaces does not have a closed form expression. Since we
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Figure 1: METAVIR standard for liver disease progression. METAVIR is a five state scoring
system for HCV where states F0-F4 represent increasing degrees of liver fibrosis. Transition
probabilities between states are identical in the METAVIR standard.
are interested specifically in Markov chains of disease progression, we are able to compare
two different such Markov chains by examining the expected time to death in each under
their respective steady state distributions. Using the expected time to death as a measure
in this way gives us an intuitive method of comparing Markov chains with different state
spaces. Since the resulting measure is in life years, the significance of the difference, or lack
thereof, between the Markov disease models is easily understood and the health implications
apparent.
In summary, our contribution is in explicitly characterizing the magnitude and direction
of the bias for several ways of calculating transition probabilities and calculating the impact
for several diseases.
2 Markov Models of Diseases
To analyze Markov disease progression models that have state dependent transition prob-
abilities, we consider models of the type in Figure 1 and compare it to the case where the
probability transitions between states are not identical. Figure 1 is a standard disease pro-
gression model used for liver disease that uses the METAVIR standard for liver disease,
which is the motivating disease for this analysis (13; 27; 16). METAVIR is a scoring system
specifically designed for HCV patients in which the scores F0-F4 represent different degrees
of liver fibrosis. F0 represents no liver scarring and F4 represent cirrhosis or advanced liver
scarring; the states in between represent intermediate levels of liver damage. Patients are
determined to be in one of the five METAVIR states via a liver biopsy. Each state in Figure
1 corresponds to a score on the METAVIR system, which are ordered by increasing liver
damage. The x values in the figure are determined by diving the time since infection by
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the number of states progressed during that time, and averaging over many patients. For
example, if a patient is determined to be in state F3 (as determined by a liver biopsy) with
an infection length of 30 years, the rate of liver disease progression is thus 3/30 = 0.1, which
is then assumed to be the constant rate of progression between all states. Consequently, the
transition probabilities are identical by construction. This method of arriving at a single
aggregate transition probability is referred to as the indirect method and is used in the ma-
jority of studies analyzing progression rates of HCV (28; 21; 29). We will refer to the value
computed using the indirect method as the indirect value.
When few patients in a data set have serial biopsies (i.e., biopsies at different points in
time for the same patient), the modeler has little choice but to use the indirect method to
estimate transition probabilities and implicitly assume constant disease progression. How-
ever, when patient data with serial biopsies is available, the modeler can potentially estimate
the transition probabilities between METAVIR states so that the disease progression is not
assumed to be constant. This study provides insight into the value of having richer disease
data (i.e., serial biopsies)
Studies involving liver disease progression typically assume a constant progression of liver
disease (12; 13; 16) as described above. Few studies allow for state dependent liver disease
progression such as done in Bennett et al. (30). Several studies have shown, however, that
liver disease progression is not constant and varies significantly between METAVIR states
(31; 32; 33; 21). Matsumura (31) and Yi, et al., (21) computed estimates for the transition
probabilities between the METAVIR states using patient data with serial biopsies in the
former, and using a Markov maximum liklihood method on single biopsy patient data in the
latter. Both studies also compute the x value using the indirect method. No studies have
analyzed, however, the consequences of using the single transition probability value that
assumes constant progression versus using the transition probabilities that vary between
states. Our study considers this issue.
Many diseases are modeled by Markov chains similar to that of Figure 1, particularly
those where the disease states represent scores on an ordinal rating system such as the
METAVIR standard. Examples include Alzheimer’s disease (AD), Glaucoma, and Amy-
otrophic Lateral Sclerosis (ALS). These diseases are progressive, sometimes degenerative,
and may or may not be fatal. The severity of AD, for example, is commonly ranked us-
ing the Mini-Mental State Examination (MMSE), which is based on a scale of 0-30. The
Alzheimer’s Disease Assessment Scale and the Blessed Information Memory Concentration








(a) constant transition probabilities












(b) time dependent transition probabilities
Figure 2: Markov models for a disease with time dependent transition probabilities.
typically grouped to represent states such as “healthy,” “mild,” “moderate,” and “severe.”
The majority of studies of AD assume a constant progression rate and use the same
single transition value between states of different severity (9; 10; 11; 14; 15). Studies that
analyze the effect of different medical interventions on AD typically measure the degree to
which the intervention decreases the constant progression rate. Jonsson (34), for example,
determined that treatment with donepezil 5 mg corresponds to multiplying the transition
probability to a state with a lower MMSE score by (1 - 0.4636) and by (1 - 0.4807) for
treatment with donepezil 10 mg. Some studies have shown, however, that the progression
is far from constant and is typically slower in less severe states (35; 36; 37). Accordingly,
some studies do use state dependent transition probabilities (38; 37). As in the case of HCV,
studies have not considered the consequences of using the single transition probability value
that assumes constant progression versus using the transition probabilities that vary between
states.
Another example of a disease that can be modeled by a Markov chain similar to Figure
1 is the progression of ALS, which is often scored on a scale of 1-5 (Mild, Moderate, Severe,
Terminal, Death) (39). Progression is often modeled as constant over time (8). Similar to
the previous examples, studies have shown, however, that ALS has nonlinear progression
(39).
For Markov disease progression models that have time dependent transition probabilities,
we consider models of the type in Figures 2(a) and 2(b). In this case, we can interpret states
1-N in Figure 2(b) as ages or as time spent in a risk state. The former is appropriate to
model diseases that progress faster with age such as HCV or AD; the latter is appropriate
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to model diseases such as lung cancer whose risk of occurrence increases with the number of
years of smoking. The model in Figure 2(b) allows for the transitions to vary with time since
the a′is can each have different values, whereas the model in Figure 2(a) does not capture
the time dependency and is equivalent to constraining the a′is to be identical in Figure 2(b).
Scherrer (18) began a framework for analyzing bias in models with time dependent transition
probabilities and compared the two models in the case of two risk states plus a disease state
for two time periods where the disease state is an absorbing state.
Scherrer (18) showed that the single transition probability of moving from the risk state
to the disease state obtained by averaging the true transition probabilities of many risk
states underestimates the likelihood of ending up in the disease state (when the probability
of transitioning to the disease state increases with time spent in the risk state, and the entire
population begins in the risk state). Scherrer also showed that the result also holds when the
population is initially evenly split between the two risk states. We extend the Markov model
in Scherrer and solve for a stationary distribution for n risk states and arrive at conditions
for bias that holds for the Markov model in steady state.
Markov models with time dependent transition probabilities of the type in Figure 2(b)
are appropriate for diseases where the transitions vary over time or by age, including HCV,
AD, lung cancer, cardiovascular disease and diabetes. In the case of HCV, many studies
utilize transition probabilities that vary by age (13; 40; 41), whereas others only use a
single transition probability that applies for all ages (16; 42) thereby not capturing the large
differences in progression by age. Our analysis studies the difference in the expected time
to progress through the METAVIR states of the HCV model using the single transition
probability versus using age dependent transition probabilities.
This model can also be used to capture other measures such as incidence. For example,
incidence of AD increases with age (43); in this case, each age of person’s life can represent a
Markov state and can have a different transition rate to the disease state. Similarly, since the
probability of acquiring lung cancer increases with the number of years of smoking (44), the
Markov states can represent the number of years of smoking, each with different transition
rates to lung cancer.
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(a) transition probabilities are constant
(b) transition probabilities are state dependent
Figure 3: Markov model for a disease with state dependent transition probabilities as used
in Monte Carlo simulations.
3 Monte Carlo Simulations of Markov Models of Dis-
eases
A common method of analyzing Markov chains of disease progression in the medical literature
is to employ the use of Monte Carlo simulations (2; 1; 16). In these models, each individual
patient’s clinical course is followed from the time of entry into the model until death or
the final state of interest is reached. The amount of time spent in each health state is
determined along with associated costs and health outcome measure such as quality adjusted
life years (QALY). Upon the patient’s death (or arrival in the final state), the next patient
is introduced into the model. The process repeats over a large number of patients and the
results are averaged over all patients. Figure 3(a) graphically represents the scenario where
we require the transition probabilities for the disease progression to be identical in a Monte
Carlo simulation, and we have generalized the number of states and introduced additional
states before and after the disease progression states. In modeling HCV, for example, state
“Healthy” represents uninfected, states “F0”-“F4” represent the METAVIR states, and the
final state before death represents disease complications including hepatocellular carcinoma




We are interested in comparing the model shown in Figure 3(a) with the model shown
in Figure 3(b). When the final state is “Death” then the direct transitions to it (from states
“Healthy - “N” ) represent death from causes other than the disease being modeled. It
is worth noting that the final state need not be “Death.” When the final state represents
a diseased state (perhaps a non-fatal disease), the direct transitions to it represent the
probability of acquiring the disease for reasons other than those captured by the model’s
states. In the case of time-dependent transition probabilities, we are interested in comparing
the model in Figures 2(b) and 2(a) where we also assume that the “death” states feeds
back into state 1 as it would in a Monte Carlo simulation. Similarly, “Death” need not be
considered the final state.
The remainder of the paper is organized as follows. We first derive at stationary distri-
butions for models where the progression changes with state or with time. Then we use the
stationary distribution to arrive at conditions for bias. We then discuss factors that affect
the degree of the bias. We apply the results to HCV, AD, and lung cancer using medical
data. Finally, we discuss the implications of the results when Markov models of disease
progression are used in studies of cost-benefit analysis, forecasting future prevalence, and
estimating future disease burden.
4 Stationary Distributions
4.1 State dependent transition probabilities
The stationary distribution of a Markov chain describes the steady state behavior of the
Markov chain, which allows us to draw conclusions about Markov models in the long run.
The results derived from the stationary distribution will hold regardless of the initial health
state or initial distribution of health states (in the case of modeling populations). The
Markov models in Figure 3 are irreducible aperiodic Markov chains where all of the states
are positive recurrent (i.e., they are ergodic). If we add a direct path from “death” to state
1 in the models in Figure 2 (as would be the case in Monte Carlo simulations), then they are
also ergodic. By Theorem 4.3.3 in Ross (45), there exists a unique stationary distribution π
for each of those ergodic Markov chains. Moreover, by Theorem 4.3.1 of Ross, the expected
return time to state i (once the state is entered) is given by 1
πi
. The death state is included
for illustrative purposes and the time spent in it is always one time period. Keeping the
death state in the model implies that 1
πDeath
− 1 represents the expected time from state
9
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Figure 4: Generalized Markov model of disease progression with state dependent transition
probabilities
“Healthy” to state “Death”. It should be clear that solving the stationary distribution of
the Markov chain in Figure 3(b) is equivalent to solving the stationary distribution of Figure
4, only differing in the labels given to the transition probabilities. Without loss of generality,
we use the Markov chain in Figure 4 in our analysis for the remainder of this paper. That is,
the results throughout this paper assume the comparison of Figure 4 to the corresponding
single probability transition Markov chain (i.e., where ai = x ∀ i). We subsequently prove,
however, that all of our results remain true in the more general case of comparing Figures
3(a) and 3(b), even when we add additional states before state 1 and after state N (as long
as they do not directly communicate with any of the states 1−N as shown in the Figures).
We begin with Figure 4 where d = 0 (i.e., there are no direct transitions to the final












1− a1 a1 0 0 · · · 0
0 1− a2 a2 0 · · · 0







0 0 0 · · · 1− aN aN
1 0 0 0 · · · 0











The proof of the solution to Equation 1 is a special case (where d = 0) of Proposition 1. All
proofs are provided in the Appendix. In the case that ai = x ∀ i, then πN = 11+N
x
.
Next we consider Figure 4 where d > 0 (i.e., there are direct transitions to the final
state). In this case the analysis is more complicated. Solving
[








1− a1 − d a1 0 0 · · · d
0 1− a2 − d a2 0 · · · d







0 0 0 · · · 1− aN − d aN + d
1 0 0 0 · · · 0


for π gives the stationary distribution.





























If we consider the case where the ai = x ∀ i as it is in the METAVIR standard and in












4.2 Time dependent transition probabilities
Next we solve for the stationary distribution to the Markov chain in Figure 2(b). In this
case, we must solve
[








0 1− a1 − d 0 0 · · · a1 d1
0 0 1− a2 − d 0 · · · a2 d2







0 0 0 · · · 0 aN dN
0 0 0 · · · 0 1−D D




Proposition 2. The stationary distribution to the Markov chain in Figure 2(b) (i.e., the












(1− ai − di)
. (8)










(1− ai − di). (9)
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Figure 2(a) is a special case (N = 3) of Figure 3(b). Consequently, we can use the
corresponding development to arrive at the expected time from state 1 to Death as
Ex =
x + d + D
(x + d)(d + D)
. (10)
If we consider the case where the ai = x ∀ i where the d′is may vary, then the expected










(1− x− di). (11)
5 Analysis of Bias
In this section, we analyze bias in the models described above. In our analysis, we take the
model with state/time dependent transition probabilities to be the status quo, and define
bias as the change in the expected time it takes to reach the final state from the initial state
when using constant transition probabilities (in place of the state/time dependent transition
probabilities).
5.1 Conditions for the existence of model bias
5.1.1 State dependent transition probabilities
For the special case where there are no direct transitions to the final state (i.e., d = 0) in
Figure 4, it follows from Equation 2 that the bias, Ba,x, resulting from the use of a single
probability transition, x, instead of the state dependent probability transitions ai, is equal
to










The model with the single transition probabilities overestimates (underestimates) the




which is the harmonic mean
of the a′is.
We turn our attention to the case when there are direct transitions to the final state (i.e.,
d > 0), which represents death from natural causes (or an alternative means of obtaining
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disease). We are interested in comparing the models in Figures 3(a) and 3(b) to analyze the
consequences of using a single transition probability. With the framework introduced in the
previous section, we can arrive at sufficient conditions for bias.
We start by subtracting Equation 6 from 5 to arrive at the expression for the difference
in the expected time from state 0 to N when using a single transition probability versus
allowing the transition probabilities to vary by state, which gives us the following Theorem.
Theorem 1. For a disease progression of the type in Figure 4, the bias resulting from the use























where we measure bias by the difference in expected time from state 0 to state N.
Theorem 1 indicates the magnitude and direction of the bias. When x is calibrated such
that the expression in 12 is zero, then there is no bias. That is, the expected time from state
0 to state N is the same when using the state dependent probabilities or that particular value
of x. Using any other value for x results in bias in the direction indicated by Theorem 1.
Next, we describe sufficient conditions on the value of x for the presence of bias.
Theorem 2. For a disease progression of the type in Figures 3(a) and 3(b), when x is less
than or equal to the harmonic mean of the a′is, and the a
′
is do not all equal x, then the
model with aggregated transition probabilities (Figure 3(a)) strictly underestimates disease
progression when compared to the model with state dependent transition probabilities (Figure
3(b)).
Theorem 2 states that the expected time from state 0 to N is larger when the harmonic
mean of the state dependent transition probabilities is used as a constant transition prob-
ability than when the state dependent transition probabilities themselves are used. That
is, model bias is strictly negative. The result holds for any value less or equal to than the
harmonic mean as well. It follows from Theorem 2 that when a value smaller than the
harmonic mean for x is used, as the value of x decreases the degree of underestimation (i.e.,
bias) increases. This is true since as x decreases, the time from state 0 to N increases, which
is apparent by examining Figure 4. The importance of Theorem 2 is that it shows that when
modeling a disease whose progression is not constant, using the harmonic mean of the state
dependent transition probabilities (instead of the state dependent transition probabilities
14
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themselves) will cause the modeler to underestimate the progression of the disease. When
using a value smaller than the harmonic mean, the modeler will increasingly underestimate
the progression of the disease.
Corollary 1. Consider a disease progression of the type in Figures 3(a) and 3(b) where the
a′is are increasing. When x is computed using the indirect method, the model with aggre-
gated transition probabilities (Figure 3(a)) strictly underestimates disease progression when
compared to the model with state dependent transition probabilities (Figure 3(b)).
Corollary 1 is a special case of Theorem 2. It is important to note than when using the
indirect method as described in section 2, the modeler can average the computed indirect
value of many patients by taking the arithmetic mean of the indirect values, or more cor-
rectly, by taking the harmonic mean of the indirect values. The choice of which mean to
use is left to the modeler, however, the harmonic mean is more appropriate when averaging
rates. When averaging the expected times between states, the arithmetic mean is more ap-
propriate. Indeed, the harmonic mean of the progression rates (indirect values) is equivalent
to the arithmetic mean of the expected times between states. The proof of Corollary 1 in
the Appendix discusses the use of the arithmetic and harmonic means further. In Corol-
lary 1, we assume x is computed by taking the harmonic mean of the indirect values of
many patients (or equivalently, the arithmetic mean of the expected times between states).
Corollary 2 discusses the case where we use the arithmetic mean of the indirect values. The
importance of Corollary 1 is that it suggests that studies that use the indirect method (the
most common method of computing constant transition probabilities) due to lack of disease
data are underestimating the disease progression for diseases such as HCV and AD that are
believed to have increasing progression rates.
Note that the converses of Theorem 2 and Corollary 1 do not necessarily follow. We can,
however, arrive at a result for model bias in the opposite direction (overestimation) using
the development in the proof of Theorem 2.
Theorem 3. For a disease progression of the type in Figures 3(a) and 3(b), when x is greater
than or equal to the geometric (or arithmetic) mean of the a′is, and the a
′
is do not all equal
x, then the model with aggregated transition probabilities (Figure 3(a)) strictly overestimates
disease progression when compared to the model with state dependent transition probabilities
(Figure 3(b)).
Theorem 3 states that the expected time from state 0 to N is smaller when the geometric
mean of the state dependent transition probabilities is used as a constant transition proba-
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bility than when the state dependent transition probabilities themselves are used. That is,
model bias is strictly positive. The result holds for any value greater than or equal to the
geometric mean, including the arithmetic mean. It follows from Theorem 3 that when a value
larger than the geometric mean for x is used (e.g., the arithmetic mean), as the value of x
increases the degree of overestimation (i.e., bias) increases. This is true since as x increases,
the time from state 0 to N decreases. The significance of Theorem 3 is that when modeling a
disease whose progression is not constant, using the geometric mean of the state dependent
transition probabilities (instead of the state dependent transition probabilities themselves)
will cause the modeler to overestimate the progression of the disease. When using a value
larger than the geometric mean, the modeler will increasingly overestimate the progression
of the disease.
Corollary 2. Consider a disease progression of the type in Figures 3(a) and 3(b) where the
a′is are decreasing. When x equals the arithmetic mean of the computed indirect values for
each patient, the model with aggregated transition probabilities (Figure 3(a)) strictly under-
estimates disease progression when compared to the model with state dependent transition
probabilities (Figure 3(b)).
Corollary 22 is a special case of Theorem 3. Contrary to Corollary 1, we assume x is
computed by taking the arithmetic mean of the computed indirect values of the patients. The
importance of Corollary 2 is that it suggests that studies that use the indirect method in this
way are overestimating the disease progression for diseases that have decreasing progression.
5.1.2 Time dependent transition probabilities
Next, we consider Markov models with time dependent transition probabilities. Subtracting
Equation 11 from 9 gives us the expression for the difference in the expected time from state
1 to state to Death when using a single transition probability versus allowing the transition
probabilities to vary over time. Solving for x gives us a condition for bias, which we formulate
as our next theorem.
Theorem 4. A Markov model without time varying transition probabilities of the type in
Figure 2(a) overestimates (underestimates) the expected time to death when compared to a
model with time dependent transition probabilities (Figure 2(b)) when
x > (<)
Ead− 1
γ − Ea (13)
16
ACCEPTED MANUSCRIPT 
where Ea is defined above and γ =
1
d+D
Theorem 4 indicates that when x equals the right hand side of inequality 13 the bias
is zero. That is, the expected time from state 1 to death is the same when using the time
dependent transition probabilities or that particular value of x. Using any other value for x
will result in bias in the direction indicated by Theorem 4.
The sufficiency theorems that are true for the state dependent transition probabilities
model are not true for the time dependent transition probabilities model. They can be shown
to be false by simple numerical counter examples, which we show in Section 6
5.2 Factors that affect the degree of model bias
Thus far we have compared models where the transition probabilities are allowed to vary
between states with models that use a single aggregate transition probability between several
states. In this section, we consider intermediate levels of data aggregation. That is, instead of
considering only the use of a single transition probability, we combine transition probabilities
in groups as shown in Figure 5, where b1 is formed by taking some mean of a1 and a2 only.
By comparing the three models in Figure 5 we will be able to analyze the effect of the degree
of data aggregation on model bias. The degree of data aggregation is increasing as we switch
from using the a′is to using the b
′
is to using c as the transition probabilities for the Markov
chain.
Theorem 5. When using any value greater than or equal to the geometric mean (e.g., the
arithmetic mean) of the transition probabilities in Figure 5, the models with aggregated tran-
sition probabilities increasingly overestimate disease progression as the degree of aggregation
increases.
It is worth recalling that the value computed using the indirect method (and averaging
over many patients using the arithmetic mean) is greater than the arithmetic mean of the
a′is for diseases that have decreasing progression.
Theorem 6. When using any value less than or equal to the harmonic mean of the transi-
tion probabilities in Figure 5, the models with aggregated transition probabilities increasingly
underestimate disease progression as the degree of aggregation increases.
Recall that the value computed using the indirect method (and averaging over many
patients using the harmonic mean) is less than the harmonic mean of the a′is for diseases

































Figure 5: Markov models of disease with different degrees of aggregation
6 Examples
In this section we use medical data to calculate the bias in models of three diseases introduced
in Section 2. We start with models whose transition probabilities vary by state and use HCV
and AD as examples. We also use HCV, AD and lung cancer to show bias in models with
time dependent transitions.
6.1 Bias in diseases with state dependent transition probabilities
In this section we use HCV and AD as examples for bias in Markov models of diseases with
state dependent transition probabilities when we aggregate the data and assume constant
transition probabilities. In the case of HCV, the progression through the METAVIR states
has been shown to vary by liver disease severity (31; 21). In this case, model states represent
METAVIR states where the transitions between states vary as shown in Table 1, where ai is
18
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the transition probability of going from state i to state i + 1. We consider several different
data sets for the same disease. The transition probability labeled “indirect” corresponds
to the single transition probability obtained using the indirect method. The indirect value
reported in each case was obtained by the same corresponding study that computed the a′is
in order to ensure that we do not introduce extra bias by using parameters derived from
different data sets.
In the case of AD, the progression has also been shown to vary significantly by severity
(36; 37). The Markov model states in this case represent the grouped MMSE scores of an
individual with AD, where the probability of transitioning between states varies according
to Table 1.
There are very few studies that compute a′is for HCV, while several studies have computed
them for AD. We chose studies that arrived at very different values for the a′is (due to
studying different populations) so that we can test for bias under very different scenarios.
For example, the a′is for Yi 1 pertain to 1138 chronic HCV patients in liver clinics who have
disproportionately faster progression than those in Yi 2, which is made up of previously
healthy women infected by exposure to contaminated anti-D immune globulin who were
then screened for HCV. The data from Matsumura (31) was obtained from Japanese patients
infected with HCV that have chronic liver disease. Similarly, while the Stern (36) and Suh
(37) data sets are on different scales, they also report very different progressions based on
the populations considered. Note that in these numerical results we assume the initial state
is the first diseased state (rather than a healty state) and set the (disease related) death rate
from the final disease state equal to one. We perform the numerical analyses in this way in
order to highlight the bias in the disease progression without confounding it with incidence
and death rates. When we performed the analyses with realistic incidence and death rates
we found that the bias directions and relative magnitudes agreed with the results contained
herein.
Table 2 displays the results for comparing the use of a single transition probability versus
using the a′is for HCV and AD. The expected time to death is displayed using the indirect
value as well as the harmonic (harm), geometric (geo) and arithmetic (arith) means, respec-
tively. We use the death rates from the Centers for Disease Control (CDC) (46). For each
data set, we compute the percent change (%4) relative to using the a′is. Note that the
indirect method results in greater bias in all cases but one (the arithmetic mean using data
from Matsumura (31) for HCV). In all cases, the harmonic mean results in less bias than




Yi 1 Yi 2 Matsumura Stern Suh
a1 0.169 0.042 0.049 0.193 0.097
a2 0.118 0.045 0.217 0.755 0.070
a3 0.225 0.097 0.556 0.859 0.053
a4 0.207 0.070 0.294 0.507
indirect 0.150 0.045 0.120 0.637 0.077
Source Yi (21) Yi (21) Matsumura (31) Stern (36) Suh (37)
Table 1: Parameter values for transition probabilities
The arithmetic mean consistently results in the largest bias among the three means. We
also compare the use of the a′is to the use of two probability transition values as in Figure
5 where we use the three different means. Using two probability transition values represents
a lower degree of data aggregation than using only one. The direction of the bias remains
constant, while the magnitude decreases as predicted by Theorems 5 and 6. In most cases,
the bias decreases significantly between using a single transition probability versus two. It
is also interesting that for the data sets where the a′is vary a great deal, the bias is much
larger.
1 transition 2 transition
probability probabilities
HCV
a′is indirect harm geo arith harm geo arith
Yi 1 19.88 21.81 19.92 19.43 19.00 19.89 19.74 19.59
%4 9.69% 0.22% -2.24% -4.42% 0.07% -0.69% -1.44%
Yi 2 40.78 45.75 41.00 39.82 38.54 40.80 40.68 40.57
%4 12.18% 0.56% -2.36% -5.48% 0.05% -0.24% -0.51%
Mat 23.08 25.66 23.90 17.20 13.40 23.52 20.11 17.17
%4 11.19% 3.56% -25.50% -41.95% 1.91% -12.86% -25.63%
AD
Stern 9.62 6.83 9.68 8.28 7.38 9.66 8.53 7.58
%4 -29.02% 0.65% -13.90% -23.31% 0.47% -11.33% -21.23%
Suh 30.12 28.24 30.22 29.65 29.09 30.14 30.00 29.85
%4 -6.24% 0.33% -1.55% -3.44% 0.08% -0.41% -0.90%
Table 2: Results for HCV and AD with state dependent transition probabilities for multiple
degrees of data aggregation
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6.2 Bias in diseases with time/age dependent transition probabil-
ities
In this section we use HCV, AD and lung cancer as examples for bias in Markov models
of diseases with transition probabilities that vary by time/age. In the case of HCV, the
progression through the METAVIR states have been shown to vary by age (13; 40; 41). The
Markov model states in this case represent ages of an individual (while infected with HCV),
where the transition to the disease state (cirrhosis) vary by age as shown in Table 3. In
the case of AD, the risk of acquiring AD has been shown to increase with age (43). The
Markov model states in this case represent the ages of an individual without AD, where the
probability of transitioning to the disease state (i.e., acquiring AD) varies by age according
to Table 4. In the case of lung cancer, we use the model in Figure 2(b) where each state
represents the number of years an individual has smoked cigarettes. In this case we use the
function
p(n) = 1.845× 10−10n4.5 (14)
as the probability of transitioning to lung cancer after smoking for n years reported in
Scherrer (18), based on Doll and Peto (47) for individuals who smoke 20 cigarettes per day
beginning at age 16.







Table 3: Liver Fibrosis estimates for HCV (13)
Table 5 displays the results for comparing the use of a single transition probability versus
using the a′is for HCV and AD. For HCV, we assume the individual acquires the disease
at age 20 and compute the expected time until death from age 20 onwards using the death
rates from the CDC (46). For AD, we consider the incidence starting at age 60 (since the
incidence before age 60 is very small) and compute the expected time to death from age 60
onwards using the same death rates. We compare the use of the harmonic, geometric and
arithmetic means. Note that the results serve as counterexamples to show that Theorems
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Table 4: Incidence of AD (43)
2 and 3 do not hold for models with time dependent transition probabilities as they do for
models with state dependent transition probabilities. The harmonic mean results in smaller
bias for both cases, however this is not necessarily always the case.
Hepatitis C, acquired at age 20
a′is arithmetic geometric harmonic
Expected time
to death from 33.91 25.16 28.89 32.32
age 20
%4 -25.79% -14.82% -4.70%
AD incidence starting at age 60
Expected time
to death from 20.75 16.52 19.47 21.35
age 60
%4 -20.35% -6.14% 2.89%
Table 5: Results for HCV and AD with time dependent transition probabilities
Table 6 displays the results for comparing the use of a single transition probability versus
using the a′is for lung cancer. We assume the individual begins smoking 20 cigarettes per
day starting at age 15 and use same death rates as previously. We compare the use of the
harmonic, geometric and arithmetic means. Note that the harmonic mean does not always
result in smaller bias. We also show the results for different levels of data aggregation. We
compare the use of the a′is to the use of two, three and four probability transition values
in the way described in Figure 5 where we use the three different means. Note that the
direction of the bias does not always remain constant. However, the bias does decrease
significantly when decreasing the degree of data aggregation. The results in Tables 5 and 6
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are not sensitive to the death rates since they are driven by the a′is.
1 transition 2 transition
probability probabilities
a′is arith geo harm arith geo harm
Expected time
to death from 59.98 45.64 61.47 62.97 57.67 61.46 59.87
age 15
%4 -23.92% 2.47% 4.97% -3.86% 2.46% -0.19%
3 transition 4 transition
probabilities probabilities
arith geo harm arith geo harm
Expected time
to death from 59.30 59.74 60.12 59.82 59.92 60.02
age 15
%4 -1.13% -0.40% 0.23% -0.28% -0.10% 0.07%
Table 6: Results for Lung Cancer with time dependent transition probabilities for multiple
degrees of data aggregation (smoking 20 cigarettes/day since 15 years old)
6.3 Transient Analysis
Since the analyses in the previous sections are based on stationary distributions, the results
hold on average and in the long term. In this section we consider the bias in the transient
periods of the Markov chain. That is, we assume an individual is initially in disease state
0, and compute the probability of the individual having reached state 4 or death at each
time period. Figures 6 and 7 illustrate this probability using the HCV data from the first
column of Table 1 and the lung cancer data described in Section 6.2, respectively. The
results indicate that the bias in disease progression during the transient periods is in the
same direction as it is in steady state, further supporting our analytical results. The same
is true for all other disease data used in this paper.
7 Discussion
When constant transition probabilities must be used due to limited data, or for analytical
tractability, caution must be exercised when choosing the value for the transition probability
in order to reduce the affect of bias. We derived sufficient conditions to test for the presence
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ACCEPTED MANUSCRIPT 
Figure 6: Probability of reaching disease state 4 or death as a function of years since HCV
infection
of bias in two different Markov models of diseases. The disease models can include state
dependent transition probabilities or time/age dependent probabilities. For the case of state
dependent transition probabilities, we also show analytically that the bias increases as the
degree of data aggregation increases, and that the increased bias is in the same direction as
determined by Theorems 2 and 3.
Bias can be significant in many cases when models use constant transition probabilities.
Using the indirect method, which is a common practice in each of the diseases discussed,
resulted in larger bias than any of the three means considered in all cases except for one.
Additionally, the bias increases dramatically when the degree of data aggregation increases.
The case where insufficient disease data causes the modeler to use the indirect method of
obtaining a constant transition probability is of particular interest since it is such a common
occurrence. We showed that the transition probability derived using the indirect method
is less than harmonic mean of the state dependent transition probabilities when they are
increasing. This result is important because it means that the use of the indirect method for
diseases with increasing progression rates leads to an underestimation of disease progression.
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Figure 7: Probability of reaching the cancer or death state as a function of number of years
smoking
We also showed that when the arithmetic mean is used to average the indirect values of
many patients, the disease progression is overestimated for diseases that have decreasing
progression rates.
It is noteworthy that many studies that produce estimates for the state dependent transi-
tion probabilities of diseases with increasing progression rates don’t always arrive at strictly
increasing transition probabilities. Results often include progression rates that increases un-
til the final states where progression then slows down, such as those used in section 6. In
light of the progressive nature of the diseases studied, the authors typically attribute the
observed slower progression in the final states due to ceiling effects of the scoring system (e.g.
MMSE), and not to the nature of the disease itself, such as in Park, et al, (48) and Aguero-
Torres et al, (49). Nevertheless, we used the transition rates as reported in the literature
and found the bias to be significant when using the indirect method.
The implication of our results is that many of the studies that assume constant tran-
sition probabilities are arriving at conclusions based on biased models, bias potentially as
large as the examples in Section 6. Analyses that use Markov models of disease progres-
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sion that ignore the state/time dependency of the probability transitions to determine the
cost-effective of medical interventions such as pharmaceutical drugs, therapies or screening
programs may be significantly biased towards or away from cost-effectiveness depending on
the type of aggregation used. A cost-effectiveness study of HCV, for example, that assumes
a constant disease progression and uses the harmonic mean (or any smaller value) for the
disease progression could potentially determine a cost-effective medical intervention to not
be cost-effective because the disease progression was underestimated.
Similarly, when estimating future prevalence, if a disease model overestimates (underes-
timates) the progression to death, ceteris paribus, then future prevalence is underestimated
(overestimated). For many diseases, the health states become costlier and associated with
lower quality of life as the disease progresses, as is the case with HCV, AD and lung can-
cer. In these cases, it is clear that if we calibrate the models such that they have the same
expected time from the first state to the final state, when the disease progression increases
(decreases) in time/state, the Markov models that use a single probability transition over-
estimate (underestimate) the time spent in the later states. This can be important since
the later states can be significantly costlier than the earlier states in the disease progression
causing the disease burden forecast to be biased.
Finally, additional bias introduced into Markov models of disease progression is due
to the fact that transition probability estimates are typically inherently underestimated.
This is true because when a patient is determined to be in a particular health state at
some point in time (by a liver biopsy, for example), there is no way of knowing how long
the patient was in that state. Consequently, the estimate for the rate of progression is
commonly made assuming the patient entered that diagnosed state in the time period of the
diagnosis. For this reason, estimates of the disease progression are typically lower bounds.
As a result, the bias introduced by the use of a single transition probability (instead of
state/time dependent probabilities) can be either increased or decreased by this measurement
effect. In the case that the use of a single transition probability causes an underestimation
of disease progression, the bias due to measurement will cause the disease progression to be
underestimated even more so than the results in Section 6 suggest.
8 Appendix
For the proofs in this appendix, it is helpful to first introduce some mathematical tools that
we will use in our analysis of model bias. We start by introducing elementary symmetric
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polynomials, which are special cases of symmetric polynomials of degree m in n variables
(where m ≤ n).
Definition 1. The elementary symmetric polynomial of degree m in n variables is defined
as




Definition 2. An alternative definition for en,m(x1, x2, · · ·xn) is that of the coefficient of xm




Next, we use the elementary symmetric polynomials in the following definition.






We use Sn,m extensively in the proofs below to simplify notation. Additionally, we use
MacLaurin’s inequality.
MacLaurin’s inequality states that
Sn,1 ≥ (Sn,1)1/2 ≥ (Sn,2)1/3 ≥ · · · ≥ (Sn,n)1/n
with equality if and only if all of the xi values are equal.
Lastly, we introduce the following Lemma, which we use to reformulate the expression for
the stationary distribution of Markov models with state dependent transition probabilities

























which we prove below.
Proof of Proposition 1
Multiplying the right hand side of Equation 3 gives
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π1 = π1(1− a1 − d) + πN
π2 = π1a1 + π2(1− a2 − d)
π3 = π2a2 + π3(1− a3 − d)
...
...
πN−1 = πN−2aN−2 + πN−1(1− aN−1 − d)
πN = πN−1aN−1 + d(π1 + π2 + · · ·+ πN−1) (16)
which can be written as
π1a1 = π2(a2 + d)
π2a2 = π3(a3 + d)
π3a3 = π4(a4 + d)
...
...
πN−1aN−1 = πN(1 + d)− d
πN = π1(a1 + d). (17)
For a stationary distribution, the relationship
π1 + π2 + π3 + · · ·+ πN = 1 (18)






(a1 + d)(a2 + d)
+
πNa1a2
(a1 + d)(a2 + d)(a3 + d)
+ · · ·+ πNa1a2 · · · an
(a1 + d)(a2 + d)(a3 + d) · · · (aN−1) + πN = 1 (19)
which can be rewritten as Equation 4. 2
Proof of Proposition 2
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Multiplying the right hand side of Equation 7 gives
π1 = πD
π2 = π1(1− a1 − d) = πD(1− a1 − d)
π3 = π2(1− a2 − d) = πD(1− a1 − d)(1− a2 − d)
...
...
πN = πN−1(1− aN−1 − d) = πD(1− a1 − d)(1− a2 − d) · · · (1− aN−1 − d)
πC = π1a1 + π2a2 + · · ·+ πNaN + πC(1−D)
πD = π1d1 + π2d2 + · · ·+ πNdN + πC(D).
Since Equation 18 must hold for a stationary distribution, rewriting Equation 18 in terms
of πD using the above equations gives us the desired expression for πD. 2
Proof of Lemma 1
Define the following string of identities
∏
1≤i≤N
(ai + d) = d
∏
2≤i≤N






(ai + d) = d
∏
3≤i≤N






(ai + d) = d
∏
4≤i≤N







(ai + d) = d
∏
N−1≤i≤N






(ai + d) = d
∏
N≤i≤N




Substituting from the bottom up recursively we have
∏
1≤i≤N
(ai + d) = d
∏
2≤i≤N
(ai + d) + da1
∏
3≤i≤N




+ · · ·+ da1a2 · · · aN−2(aN + d) + da1a2 · · · aN−1. (20)
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(ai + d) + a1
∏
3≤i≤N
(ai + d) + a1a2
∏
4≤i≤N









(ai + d) + a1
∏
3≤i≤N
(ai + d) + a1a2
∏
4≤i≤N
(ai + d) + · · ·+ a1a2 · · · aN−1.
From Equation 20 we have
∏
1≤i≤N





Proof of Theorem 2
We start by analyzing the Markov disease model in Figure 4 and compare it to the case
where ai = x ∀ i. Then we extend the result to be true in the more general case of Figures







From Equation 6, for the disease progression in Figure 4, we know that the expected time











































ai = eN,N , we can rewrite Equation 21 as
Ea =
dN−1 + eN,1dN−2 + eN,2dN−3 + · · ·+ eN,N−1d
dN + eN,1dN−1 + eN,2dN−2 + · · ·+ eN,N−1d + eN,N .
Finally, dividing both numerator and denominator by eN,N we get
Ea =
eN,Nd
N−1 + eN,N−1dN−2 + eN,N−2dN−3 + · · ·+ eN,1
eN,NdN + eN,N−1dN−1 + eN,N−2dN−2 + · · ·+ eN,1d + 1 (22)





,· · · 1
aN
.
Note that since the denominator can be written by multiplying the numerator by d and






n−1 + eN,N−1dN−2 + eN,N−2dN−3 + · · ·+ eN,1.
We can arrive at a similar expression for the expected time from state 0 to state N in
the model with aggregated transition probabilities where we have x′s instead of a′s. Using









































Similarly, since the denominator can be written by multiplying the numerator by d and
























dN−3 + · · ·+ N
x
.
We would like to compare the expected time from state 0 to state N using a′s with the







then it follows that the model in which x′s are used underestimates the disease progression
since the expected time from state 0 to state N is longer. Since the inequality in 24 is always
true whenever B > A, we need only to show that
eN,N︸︷︷︸
a
dN + eN,N−1︸ ︷︷ ︸
b
dN−1 + eN,N−2︸ ︷︷ ︸
c












































Next we must show that the terms labeled a, b, c, · · · are strictly less than the terms





























= SN,1 and by Maclaurin’s inequality SN,1 > (SN,m)
1
m for all m
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whenever the ai are not all equal, then inequality 26 is always true. 2
Proof of Corollary 1
Given Theorem 2, we need only to show that when the a′is are increasing, the value
computed using the indirect method is less than the harmonic mean of the a′is. The indirect
method is computed without taking into account death from other causes (i.e., when d = 0).
It is a well known property of the harmonic mean that it equals the arithmetic mean of the
reciprocals. Since ai represents the transition probability from state i to i + 1, when d = 0
the expected time from state i to i + 1 is 1
ai
:= ti. Consequently, the harmonic mean of
the a′is is equal to the arithmetic mean of the t
′
is. When the a
′
is are increasing (i.e., t
′
is are

















(t1 + t2 + · · ·+ tN)
=
N
(1/a1 + 1/a2 + · · · 1/aN) (28)
which is equal to the harmonic mean of the a′is. 2
Proof of Theorem 3
As in the proof of the previous theorem, we start by analyzing the Markov disease model
in Figure 4 and compare it to the case where ai = x ∀ i. We start with Equations 22 and








which is true when B < A. In this case, we must show that the expression on the left hand
side of Equation 25 is greater than the expression on right hand side of Equation 25. By









which is the reciprocal of the geometric mean of the a′is. It remains to show that the terms
labeled b, c, · · · , d are strictly greater than the terms labeled b′, c′, · · · , d′ in inequality 25
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for all m whenever the ai are not all equal, then inequality 31 is always true. Since the
geometric mean is always less than or equal to the arithmetic mean, the result holds for the
arithmetic mean as well. 2
Proof of Corollary 2
Given Theorem 3, we need only to show that when the a′is are decreasing, the arithmetic
mean of the indirect values of the patients is greater than the arithmetic mean of the a′is.
When the a′is are decreasing, the t
′
is are increasing, and we can see that the arithmetic mean










+ · · · N
















(a1 + a2 + · · ·+ aN), (33)
which is equal to the arithmetic mean of the a′is. 2
Proof that Theorems 2 and 3 are true in the general case of the model in Figure
3(b).



























(a1 + d)(a2 + d)
+
a1a2
(a1 + d)(a2 + d)(a3 + d)
+ · · ·+ a1a2 · · · an














We want to show that the inequality remains true when we add the transition probabilities
i, z, and D to the stationary distribution according to the Markov model in Figure 3(b). By
updating Equation 19 (where we derived the stationary distribution) to include i, z, and D,





(i + d)(a1 + d)
+
ia1
(i + d)(a1 + d)(a2 + d)
+ · · ·+ ia1 · · · anzD






(i + d)(x + d)
+
ix
(i + d)(x + d)2
+ · · ·+ ix
NzD
(i + d)(x + d)N−1(z + d)(D + d)
which is clearly true whenever inequality 34 is true. The result is also true for the reverse
inequality. 2
Proof of Theorem 5
To show that bias increases as the degree of aggregation increases, we must prove that
Ea > Eb > Ex
when the a′is and b
′
is are not all equal to x, and b1 =
√
a1a2 and b2 =
√
a3a4. Ea > Ex and
Eb > Ex are true by Theorem 3 from the previous section. It remains to show that Ea −Eb
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is strictly positive, which expands to
Ea − Eb = (35)
a1a2a3a4






(−2√a1a2d2 − 2d2√a3a4 + a2da4 + a1a3a4 + a1da3 + a1da4 + d2a3 + a2a3a4 (37)
+a2d
2 + a2a3d + a1a2a4 + a1a2a3 + a1d
2 + d2a4 − 2a3a4√a1a2 − 4√a1a2√a3a4d
−2a1a2√a3a4)/((a1 + d)(a2 + d)(a3 + d)(a4 + d)(√a1a2 + d)2(√a3a4 + d)2).
Since the fraction in line 36 is always positive, it suffices to show that lines 37 - 38 are
strictly positive. These lines can be rewritten as a polynomial in d as
d2 (−2√a1a2 + a1 + a2 + a3 + a4 − 2√a3a4)
+d (a1a3 + a1a4 + a2a4 + a2a3 − 4√a1a2√a3a4)
+ (−2a1a2√a3a4 − 2a3a4√a1a2 + a1a2a4 + a1a3a4 + a2a3a4 + a1a2a3).
Next we show that each coefficient of the powers of d is strictly positive. Rewriting the































The above inequalities are true by repeatedly applying the inequality of the arithmetic






whenever a1 6= a2 (which is a special case of the Maclaurin inequality where n=2). It should
be clear that the result holds for any mean greater than or equal to geometric mean. In the
same way that Theorems 2 and 3 were shown to still be valid in the more general setting
where we include additional states before and after the disease progression, this theorem is




Proof of Theorem 6
We omit the proof since it very closely follows that of Theorem 5, where instead of using




whenever a1 6= a2 and a1, a2 > 0 which can be seen to be true since (a1 + a2)2 > 0. It should
be clear that the result holds for any mean less than or equal to the harmonic mean. In the
same way that Theorems 2 and 3 were shown to still be valid in the more general setting
where we include additional states before and after the disease progression, this theorem is
also true in the more general setting. 2
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